Welcome to the Office of Cancer Survivorship Program, DCCPS
The NCI Office of Cancer Survivorship (OCS) works to enhance the quality and length of survival of all persons diagnosed with cancer and to prevent, minimize, or manage adverse effects of cancer and its treatment.
Join the Office of Cancer Survivorship on October 25, 2022, 2-3 p.m. ET for the next OCS Director’s Series webinar. Dr. Ronald Epstein will present Beyond Prognostic Information – What Survivors Need, and lung cancer survivor and advocate Jill Feldman will share her experiences. Register now for this upcoming event.
On September 27, 2022, 2-3 p.m. ET, Dr. Eric Chow and Dr. Sherry-Ann Brown will present Cardio-oncology: Collaborating to Improve Cardiovascular Outcomes in Cancer Survivors. Register now for this upcoming event.
OCS created the New Investigators Series to support those who are early in their career in cancer survivorship research. Find recordings from successful researchers, and save the date for an upcoming webinar on November 15th, 2-3 p.m. ET: Best Practices for Advocate Engagement. More info to come.
NCI researchers report that as of 2018, there were an estimated 623,405 people living with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma, and that number is expected to increase to 693,452 by the year 2025. View a preprint of the article in JNCI.
About The Office of Cancer Survivorship
An individual is considered a cancer survivor from the time of diagnosis, through the balance of life. There are many types of survivors, including those living with cancer and those free of cancer. This term is meant to capture a population of those with a history of cancer rather than to provide a label that may or may not resonate with individuals.
OCS works to promote a better understanding of unique needs of the growing population of cancer survivors, and to enhance our ability to address them.
Featured Graph and Statistic
Researchers at the National Cancer Institute have estimated that 623,405 people in the United States were living with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma as of 2018, and that number is expected to increase to 693,452 by the year 2025.